CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of...
Phase 1, Phase 2
Villejuif, France and 26 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Paris, France and 88 other locations
multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma...
Phase 2
Villejuif Cedex, France and 16 other locations
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...
Phase 1
Paris, France and 31 other locations
focused on patients who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come bac...
Phase 3
Paris, Cedex 10, France and 60 other locations
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....
Phase 1, Phase 2
Villejuif, France and 50 other locations
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...
Phase 2
Paris, France and 59 other locations
dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...
Phase 1, Phase 2
Paris, France and 104 other locations
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...
Phase 2
Paris, Ile-de-France, France and 93 other locations
Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...
Phase 3
Paris 10, France and 66 other locations
Clinical trials
Research sites
Resources
Legal